Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 20 Jun 2024
FDA approval of Sofdra - the first new drug for primary axillary hyperhidrosis
20 June 2024 - FDA approval was supported by results from the two pivotal Phase 3 studies evaluating the efficacy ...
Posted by Michael Wonder on 20 Jun 2024
Too much politics clouding cancer drugs process, decision - PHARMAC minister
20 June 2024 - There is a danger cancer patients are being overlooked in the political points-scoring that has arisen ...
Posted by Michael Wonder on 20 Jun 2024
The value of the quality adjusted life years
19 June 2024 - Concerns about quality-adjusted life years (QALYs) being discriminatory have reached a fever pitch in the US, culminating ...
Posted by Michael Wonder on 20 Jun 2024
Quality use of medicines: who owns it now?
18 June 2024 - In December 2022 after 24 years, NPS MedicineWise was closed, thus ending its role as an independent, ...
Posted by Michael Wonder on 20 Jun 2024
Quality adjusted life years, quality adjusted life year like measures, or neither? The debate continues.
19 June 2024 - The quality-adjusted life year (QALY) is over 50 years old. Debate about the ethical basis for the ...
Posted by Michael Wonder on 20 Jun 2024
What good are whizzy new drugs if the world can’t afford them?
14 June 2024 - Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson. ...
Posted by Michael Wonder on 20 Jun 2024
Truqap plus Faslodex approved in the EU for patients with advanced oestrogen receptor positive breast cancer
20 June 2024 - Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or ...
Posted by Michael Wonder on 20 Jun 2024
Golidocitinib approved in China as first in class JAK1 only inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma
19 June 2024 - Golidocitinib is a first-in-class Janus kinase 1 only inhibitor approved for the treatment of relapsed/refractory PTCL based ...
Posted by Michael Wonder on 20 Jun 2024
KalVista submits new drug application to FDA for sebetralstat as first oral on-demand treatment for hereditary angioedema
18 June 2024 - KalVista Pharmaceuticals today announced the submission of a new drug application for US FDA review of ...
Posted by Michael Wonder on 20 Jun 2024
Aurion Biotech receives breakthrough therapy designation and regenerative medicine advanced therapy designation for its drug candidate AURN001
19 June 2024 - First allogeneic cell therapy to receive both FDA designations for the treatment of corneal oedema secondary to ...
Posted by Michael Wonder on 19 Jun 2024
European Commission grants Sobi marketing authorisation for Altuvoct for treatment of haemophilia A
19 June 2024 - Sobi today announced the European Commission has granted marketing authorisation for Altuvoct's (efanesoctocog alfa), for the ...
Posted by Michael Wonder on 19 Jun 2024
National cancer drug promise: PHARMAC Minister won’t guarantee those 13 drugs will be funded
19 June 2024 - The minister responsible for New Zealand’s drugbuying agency PHARMAC is at odds with the Minister of ...
Posted by Michael Wonder on 19 Jun 2024
How AI is revolutionising drug development
17 June 2024 - In high-tech labs, workers are generating data to train AI algorithms to design better medicine, faster. But ...
Posted by Michael Wonder on 19 Jun 2024
Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy (final guidance)
19 June 2024 - NICE has published final evidence-based recommendations on the use of tafamidis meglumine (Vyndaqel) for the treatment ...
Posted by Michael Wonder on 19 Jun 2024
US FDA approves Skyrizi (risankizumab-rzaa) for ulcerative colitis, expanding AbbVie's portfolio across inflammatory bowel disease
18 June 2024 - Approval supported by two Phase 3 clinical trials that evaluated Skyrizi for the treatment of moderate to ...